Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (255)	2/2/1999 4:21:00 PM
From: Spartex	Read Replies (2) of 3557

MZ, << Unfortunately, REGN discontinue (for now, and I hope forever)development of the NT3 for diabetic neuropathy. REGN is currently running small PII trials for GI indications.>> What is your rationale for favoring REGN to discontinue NT3 development "forever"? Being a diabetic, and still healthy, I'd love to see some progress on a drug that minimizes/reverses the onset of neuropathy, wouldn't you? BTW, nice explosion upward today. Regards, QuadK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next